Vector-borne diseases (VBDs) represent a significant public health challenge in India, with increasing incidence and geographical spread.
India bears a high burden of VBDs, including malaria, dengue, and chikungunya, which are associated with high morbidity and mortality. Climate change, urbanization, and inadequate vector control are key contributing factors.
The healthcare system's response includes early detection, prompt treatment, and integrated vector management. However, challenges persist due to resource constraints and gaps in surveillance.
Healthcare professionals play a crucial role in managing VBDs, from clinical management to public health advocacy. Their active participation is needed to enhance disease surveillance, patient education, and community engagement.
Addressing the escalating challenge of VBDs in India requires a multifaceted approach, involving healthcare professionals, policy-makers, and communities. Strengthening the healthcare system's response and enhancing professional capacity are key to mitigating this public health threat.
1.
High Rate of Surgical Success in Complex NSCLC With Neoadjuvant Chemoimmunotherapy
2.
Papillary thyroid cancer: New markers offer hope for tailored treatment
3.
What Comes After Cancer?
4.
FDA Expands Durvalumab Label to Operable Lung Cancer
5.
In postmenopausal women with hormone receptor-positive tumors, obesity increases the risk of breast cancer recurrence.
1.
Finding Support: Connecting with the Vitiligo Community
2.
Essential Updates in Hematology in Daily Practice
3.
Neoepitope Vaccines in Oncology: Precision, Sequencing, and Immunotherapy Frontiers
4.
Living Better With Advanced Cancer Through Supportive Care
5.
Understanding Epoetin and Its Role in Treating Chronic Kidney Disease
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
2.
Updates on Standard V/S High Risk Myeloma Treatment
3.
What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?
4.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II
5.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation